Lupin Healthcare (UK), a wholly-owned subsidiary of Lupin (NSE:LUPIN, BOM:500257), has acquired the entire share capital of UK-based Renascience Pharma for 12.3 million pounds sterling, according to a Wednesday filing to the Indian stock exchanges.
Renascience Pharma is a licensee and sole supplier of four niche BioGenerics products to primary and secondary care market in the UK.
Its portfolio includes two injectables for (non-viral) infectious diseases, ear drops for pain management and oral therapy for indications in cardiology and nephrology.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.